Assessment of pulmonary arterial stiffness in patients with systemic sclerosis without overt pulmonary hypertension

Metin Çoksevim1 · İdris Buğra Çerik2 · Mustafa Yenerçağ3 · Ahmet Onur Kocasarı1 · Gökhan Yavuzbilge4 · Musa Polat5 · Murat Meriç1 · Metin Özgen4

Received: 9 February 2022 / Accepted: 17 April 2022 / Published online: 28 May 2022
© The Author(s), under exclusive licence to Springer Nature B.V. 2022

Abstract
Pulmonary hypertension (PH) is a pathophysiological disorder that may involve multiple clinical conditions and complicate most systemic diseases. Systemic sclerosis (SSc), represents the leading cause of connective tissue disease (CTD) associated with PAH. Although SSc is a rare disease, it is associated with higher morbidity and early mortality than other rheumatological diseases due to developing SSc-associated interstitial pulmonary disease (ILD) and/or pulmonary arterial hypertension (PAH). The impact of the early diagnosis on the prognosis is evident. In this context, in our study, we aimed to investigate the early changes in pulmonary vascular bed by measuring pulmonary arterial stiffness (PAS) in SSc patients without overt PAH. Sixty-two SSc patients and fifty-eight gender and age-matched, healthy subjects enrolled in this cross-sectional observational study. SSc patients were evaluated in terms of disease duration and severity. Modified rodnan skin score (mRSS) was calculated as disease severity index. Echocardiographic parameters were assessed and compared to the control group. Right ventricular (RV) diameters, systolic pulmonary artery pressure (sPAP), and right ventricle myocardial performance index (RV-MPI) were significantly higher in the SSc group compared to the control group (p < 0.05). Tricuspid annular plane systolic excursion (TAPSE) and right ventricular fractional area change (RVFAC) were significantly lower in the SSc group compared to the control group (p < 0.05). PAS value (25.5 ± 9.2 kHz/ms vs. 18.1 ± 7.4 kHz/ms, p < 0.001) was significantly higher in the SSc group than in the control group. A statistically significant positive correlation relationship was detected between the PAS value and CRP, ESR, disease duration, mRSS. According to these results, in SSc patients, PAS as an inexpensive and easily applicable echocardiographic method might serve as a marker of early detection of PAH.

Keywords  Pulmonary arterial stiffness · Systemic sclerosis · Pulmonary hypertension · Screening · Early detection

Introduction
Pulmonary hypertension (PH) is a pathophysiological disorder that may involve multiple clinical conditions and complicate most systemic diseases. PH is a common disorder affecting approximately 1% of the global population and about 10% of patients older than 65. Elevation of pulmonary artery pressure (PAP) may result from various underlying causes [14].

Systemic sclerosis (SSc) is a chronic and progressive autoimmune disease. Skin and many other organ involvements can occur [31]. Although SSc is a rare disease, it is associated with higher morbidity and early mortality than other rheumatological diseases as a result of developing SSc-associated interstitial pulmonary disease (ILD) and/or pulmonary arterial hypertension (PAH) [21, 28]. In Western countries, PAH associated with connective tissue disease
(CTD) is in second place after idiopathic PAH for etiology of PH. PAH is the leading cause of death in SSc patients [14]. SSc, particularly in its limited variant, represents the leading cause of CTD associated with PAH in Europe and the USA [14].

Precapillary PH was found in 5–12% of SSc patients in large-scale cohort studies [2]. Current guidelines recommend annually screening with biomarkers and respiratory function tests in addition to resting echocardiography for asymptomatic SSc patients [14]. Because it is well known that; earlier detection of PAH is associated with more favorable clinical outcomes [7, 14].

Transthoracic echocardiography (TTE) has a crucial role in PH diagnostic and screening strategy [29]. Early changes can be detected by pulmonary arterial stiffness (PAS) measurement during the beginning stages of pulmonary hypertension development [17]. PAS can be easily obtained by dividing the pulmonary flow peak velocity by the pulmonary flow acceleration time (PAT) [13, 16].

SSc-associated PAH can be diagnosed after 10–15 years of initial diagnosis of SSc [19]. The impact of the early diagnosis on the prognosis is evident. In this context, in our study, we aimed to investigate the early changes in pulmonary compliance and whether an early clinical evaluation could be made by PAS in SSc patients without overt PAH.

**Methods**

**Study population**

Sixty-two SSc patients who fulfilled the American College of Rheumatology criteria for diagnosis [30] and fifty-eight gender and age-matched, healthy subjects attended the cardiology and rheumatology outpatient clinics between May 2021, and January 2022 enrolled in this cross-sectional observational study.

Exclusion criteria were; congenital heart disease, portal hypertension, HIV infection, coronary artery disease, structural heart disease or heart failure, heart valve disease (more than mild), chronic obstructive pulmonary disease (COPD), obstructive sleep apnea syndrome, other CTD or drugs which are involved in PH etiology, chronic thromboembolic PH (CTePH), hematological disease, chronic renal failure, and inadequate echocardiographic imaging. Patients with a peak tricuspid regurgitation velocity greater than 3.4 m/s on echocardiography were also excluded because of the strong correlation between right heart catheterization (RHC) and this estimated cutoff level [18].

During the enrollment process, two patients with chronic PAH, three patients with peak tricuspid regurgitation velocity more than 3.4 m/s (newly diagnosed), one patient with end-stage renal disease (ESRD), one patient with left ventricular (LV) systolic dysfunction, and one patient with COPD were excluded according to exclusion criteria. Finally, a total of 54 patients were analyzed (Fig. 1).

All participants were informed about the investigation protocol, and all patients signed a written consent form. The local ethics committee approved the study design and methodology with reference number OMUKAEK 2020/384.

**Data collection**

All subjects had a complete history and physical examination. Basic demographic characteristics, including age, gender, body mass index (BMI), systolic and diastolic blood pressure (BP), and heart rate of the whole population, were recorded. TTE was performed on all study participants.

An experienced rheumatologist evaluated the patients with SSc in terms of disease duration and severity, and presence of digital ulcer, Raynaud’s phenomenon, and specific visceral involvements such as skin, gastrointestinal, pulmonary, or musculoskeletal.

Clinical data such as routine laboratory tests, immunological markers, and data concerning SSc-related involvements were obtained from recent medical records.

**Echocardiography**

Two experienced echocardiographers who were blinded to the study performed TTE systematically on all participants. Vivid E9 (GE Vingmed Ultrasound, Horten, Norway) TTE device and M5S (1.5–4.5 MHz) ultrasound probe was used for the measurements. TTE was performed in the left lateral
decubitus position after resting for at least 15 min. Left ventricle end-diastolic (LVEDD) and end-systolic diameters (LVESD), and left atrium (LA) anteroposterior diameter was measured from the long-axis view. Ejection fraction (EF) was calculated by the modified simpson method using apical four-chamber and two-chamber images, mitral inflow velocities to assess LV filling, including mitral early diastolic inflow velocity (E), atrial late filling peak velocity (A), deceleration time (DT), and E/A ratio, also were measured in apical four-chamber view. The peak velocities of early diastolic waves (septal e’and lateral e’) were measured by PW tissue doppler imaging (TDI) from the lateral and septal walls of the left ventricular basal section. E/e’ (septal) ratio was calculated. Valvular heart pathologies were detected and graded.

Right ventricular (RV) diameters were measured at RV mid and basal region and the total length from apical four-chamber view. Percentage right ventricular fractional area change (RV-FAC) was calculated by dividing the difference in RV area between the end-diastolic and end-systolic phases by end-diastolic RV area. Tricuspid annular plane systolic excursion (TAPSE) is defined as the distance between end-diaostole and end-systole at the lateral corner of the tricuspid annulus. Systolic PAP (sPAP) was calculated as the sum of the right atrial pressure value obtained by Bernoulli’s equation from tricuspid valve pressure gradient and caval respiratory index. Calculation of the RV myocardial performance index (RV MPI) was assessed by pulse wave (PW) tissue doppler imaging (TDI). In addition, isovolumic contraction time (IVCT), ejection time (ET), and isovolumic relaxation time (IVRT) was calculated by using PW TDI. RV MPI was measured using the Tei index. To measure RV S’, RV-focused view is used with tissue doppler region of interest placed at the lateral corner of the tricuspid annulus acquired at high frame rate. The velocity S’ is read as the highest systolic velocity. All echocardiographic assessments were performed based on recommendations of the American Society of Echocardiography guidelines [24].

**Definitions**

**Measurement of pulmonary arterial stiffness**

First of all, the pulmonary artery was visualized from the apical short axis. After that, the pulse wave doppler measurement of pulmonary flow was taken 10–15 mm below from the pulmonary valve.

PAS is defined as the ratio between maximum frequency shift (MFS) of the pulmonary flow and pulmonary flow acceleration time (PAT). MFS was measured from the peak velocity of the pulmonary flow, as shown in Fig. 2. PAT is defined as the time from the onset of pulmonary flow ejection to the peak moment (Fig. 2). Measurements were repeated at least five consecutive beats, and the averages of measurements were calculated.

\[
PAS = \frac{\text{MFS (Hertz)}}{\text{PAT (ms)}}
\]

**Rodnan skin score**

Skin thickening is a characteristic feature of SSc. More extensive skin involvement coincides with more severe internal organ manifestations, poor prognosis, and increased disability in SSc patients. The fully validated, feasible gold standard method for measuring skin involvement is the

---

**Fig. 2** Evaluation of pulmonary arterial stiffness (PAS). PAS = MFS/PAT. MFS maximum frequency shift, PAT pulmonary flow acceleration time.
modified Rodnan skin score (mRSS) [11]. mRSS was calculated for all SSc patients by an experienced rheumatologist.

**Statistical analysis**

All data were analyzed using “SPSS (Statistical Package for Social Sciences) for windows 21.0 (SPSS Inc, Chicago, IL). The continuous variables were tested for a normal distribution using the Kolmogorov–Smirnov test. Normally distributed data were presented as the mean ± standard deviation and non-normally distributed data as the median with an interquartile range. The categorical variables were expressed as percentages. Intra- and inter-observer reliability was calculated by intraclass correlation coefficients (ICC) analysis. For comparison of quantitative data, Student’s t-Test (normally distributed data) and Mann Whitney-U test (non-normally distributed data) were used. Categorical variables were compared with the Chi-square test. Spearman’s correlation coefficient tests were used to assess the strength of the relationship between PAS and CRP, ESR, disease duration, mRSS. The results were evaluated within a 95% confidence interval. A p value < 0.05 was considered to indicate statistical significance.

**Results**

Demographic, clinical, and laboratory variables of the study population are demonstrated in Table 1. The mean age of the participants was 49.7 ± 14.5 years, and 85.5% were female. There were no significant differences between the two groups regarding baseline variables (p > 0.05). ESR (erythrocyte sedimentation rate) and CRP (C-reactive protein) values were significantly higher in the SSc group than the control group (p < 0.05). TAPSE, RV S' and RV-FAC were significantly higher in the SSc group compared to the control group (p < 0.05). PAS value was significantly higher in the SSc group than the control group (25.5 ± 9.2 kHz/ms vs. 18.1 ± 7.4 kHz/ms, p < 0.001, respectively). Intra- and inter-observer agreements were 0.97 and 0.93 for PAS measurements, respectively (p < 0.001). The relationships of the PAS with CRP, ESR, disease duration, mRSS was evaluated via Spearman’s correlation analyses. The results yielded by Spearman’s correlation analysis are presented in Table 4.

**Discussion**

In the present study, a statistically significant increase of PAH was demonstrated in patients with SSc without overt PAH compared to healthy individuals. Our results are important in terms of providing data for early deformation in pulmonary vascular bed in this patient group. As a result of our study, we demonstrate a positive correlation between the PAS and the disease duration and severity indexes such as mRSS or ESR and CRP levels in patients with SSc. A statistically significant positive correlation relationship was detected between the PAS value and CRP, ESR, disease duration, mRSS.

Numerical variables are presented as mean ± SD and categorical variables as percentages. Non-normally distributed data as the median with an interquartile range

| Variables Scleroderma group (n=45) | Control group (n=45) | p value |
|----------------------------------|----------------------|--------|
| Age, years                       | 49.5±14.6            | 50.2±15.1 | 0.193 |
| Gender, female, n (%)            | 39 (86.7)            | 38 (84.4) | 0.853 |
| Smoking, n (%)                   | 7 (15.5)             | 8 (17.7) | 0.772 |
| BMI, kg/m²                       | 23.5±3.1             | 23.1±3.3 | 0.445 |
| HT, n (%)                        | 13 (28.8)            | 12 (26.6) | 0.552 |
| DM, n (%)                        | 10 (22.2)            | 9 (20) | 0.401 |
| Hyperlipidemia, n (%)            | 6 (13.3)             | 7 (15.5) | 0.369 |
| SBP, mmHg                        | 125±12.6             | 123±11.5 | 0.112 |
| DBP, mmHg                        | 69.9±8.9             | 70.2±9.1 | 0.124 |
| White blood cell, 10³ uL         | 7.9±4.3              | 7.4±4.6 | 0.092 |
| Hemoglobin, g/dl                 | 12.7±1.7             | 13.2±1.6 | 0.126 |
| Platelet, 10³ uL                 | 360.5±72.2           | 355±70.2 | 0.086 |
| Creatinin, mg/dl                 | 0.97±0.31            | 0.94±0.41 | 0.157 |
| ALT, IU/l                        | 17.1±1.7             | 16.9±2.6 | 0.102 |
| AST, IU/l                        | 12.2±2.6             | 12.5±2.4 | 0.198 |
| CRP, mg/dL                       | 5 (10–2)             | 2 (6–1)  | <0.001 |
| ESR, mm/h                        | 26 (41–10)           | 11 (15–4) | <0.001 |

Table 1 Baseline characteristics, medical history and laboratory findings of the study population
or the Australian scleroderma interest group (ASIG), which PAH in SSc patients. Various algorithms such as DETECT strategy to implement in screening for the development of patients [14, 15, 20]. There is no definite consensus on what at least annually echocardiographic evaluation for all SSc screening must be planned [8]. Current guidelines suggest in SSc, patients should be evaluated more carefully, and prevalence of PAH amongst the various CTD is observed with an unknown duration in SSc [6, 7]. As the highest increased sPAP. However, there is a silent pre-clinical period of breath due to cardiopulmonary involvement especially tricuspid dysfunction [13].

During PAH progression, an imbalance occurs between the mediators that control vasomotor tone that leads to irreversible remodeling of the pulmonary vessels due to vasoconstriction, vascular endothelial cell proliferation, and vascular smooth muscle hypertrophy [28]. Remodeling of the pulmonary vessels causes impairment in pulmonary elasticity [5]. Previous studies demonstrated that changes in elasticity are primarily due to an increase in PAP [9]. In their research, Friesen et al. examined 56 patients with PAH and found that PAS assessed by cardiac magnetic resonance (CMR) non-invasively is a major contributor to right ventricle dysfunction [13].

SSc patients can be presented with dyspnea, or shortness of breath due to cardiopulmonary involvement especially increased sPAP. However, there is a silent pre-clinical period with an unknown duration in SSc [6, 7]. As the highest prevalence of PAH amongst the various CTD is observed in SSc, patients should be evaluated more carefully, and screening must be planned [8]. Current guidelines suggest at least annually echocardiographic evaluation for all SSc patients [14, 15, 20]. There is no definite consensus on what strategy to implement in screening for the development of PAH in SSc patients. Various algorithms such as DETECT or the Australian scleroderma interest group (ASIG), which

### Table 2 Clinical data of the systemic sclerosis population

| Variables                        | Scleroderma group (n=45) | Control group (n=45) | p value |
|----------------------------------|--------------------------|----------------------|---------|
| Disease duration, years          | 8.1 ± 7.5                | 8.1 ± 5.8            | 0.741   |
| mRSS                             | 13.9 ± 6.5               | 13.4 ± 5.7           | 0.317   |
| Raynaud’s phenomenon, n (%)      | 38 (84)                  | 40 (78)              | 0.548   |
| Digital ulcer, n (%)             | 15 (33)                  | 12 (22)              | 0.211   |
| Esophageal involvement, n (%)    | 6 (13)                   | 6 (11)               | 0.224   |
| Antinuclear antibodies (positive), n (%) | 43 (95)    | 40 (71)              | 0.212   |
| Antitopoisomerase I antibodies (positive), n (%) | 22 (48) | 21 (37)              | 0.224   |

**Drug treatments**

- Plaquenil, n (%) 35 (77)
- Methotrexate, n (%) 5 (11)
- Mycophenolate mofetil, n (%) 8 (17)
- Prednisolone, n (%) 12 (26)
- Azathioprine, n (%) 7 (15)
- Calcium channel blockers, n (%) 14 (31)
- anti-TNF monoclonal antibody, n (%) 2 (4)

Numerical variables are presented as mean ± SD and categorical variables as percentages

mRSS modified Rodnan skin score, TNF Tumor necrosis factor

### Table 3 Echocardiographic characteristics of study population

| Parameters                   | Scleroderma group (n=45) | Control group (n=45) | p value |
|------------------------------|--------------------------|----------------------|---------|
| Heart beats, bpm             | 70 ± 8                   | 71 ± 6               | 0.475   |
| LVEF, %                      | 61.5 ± 1.4               | 61.7 ± 1.2           | 0.254   |
| LVESD, mm                    | 30.1 ± 1.7               | 31.1 ± 1.3           | 0.135   |
| LVEDD, mm                    | 44.2 ± 3.3               | 43.7 ± 3.4           | 0.118   |
| LVSWT, mm                    | 10.2 ± 0.7               | 10 ± 0.6             | 0.302   |
| PWT, mm                      | 9.2 ± 0.5                | 9 ± 0.6              | 0.136   |
| LAD (a-p), mm               | 31.8 ± 4.7               | 30.8 ± 4.2           | 0.099   |
| sPAP, mmHg                   | 26.4 ± 4.4               | 23.1 ± 5.5           | < 0.001 |
| E/e’ (septal) ratio          | 9.1 ± 2.7                | 8.9 ± 2.6            | 0.041   |
| RV mid-diameter, mm          | 27.1 ± 3.1               | 25.9 ± 2.1           | < 0.001 |
| RV basal-diameter, mm        | 31.3 ± 3.3               | 30.6 ± 2.9           | 0.045   |
| RV-FAC, %                    | 40.4 ± 4.4               | 43.4 ± 5.8           | < 0.001 |
| RV S’ cm/s                   | 11.3 ± 2.2               | 12.1 ± 2.3           | 0.008   |
| Tissue doppler RV-MPI        | 0.50 ± 0.03              | 0.44 ± 0.08          | < 0.001 |
| TAPSE, mm                    | 22.1 ± 4.4               | 24.4 ± 2.6           | < 0.001 |
| PAS, kHz/ms                  | 25.5 ± 9.2               | 18.1 ± 7.4           | < 0.001 |

Statistically significant values (p < 0.05) were written in bold

Numerical variables are presented as mean ± SD and categorical variables as percentages. Non-normally distributed data as the median with an interquartile range

Bpm beats per minute, LVEF left ventricular ejection fraction, LVEDD left ventricular end-diastolic diameter, LVESD left ventricular end-systolic diameter, LVSWT left ventricular septal wall thickness, PWT posterior wall thickness, LAD (a-p) left atrium diameter anterior–posterior, RV right ventricle, RV-FAC % right ventricular fractional area change percentage, RV-MPI right ventricular myocardial performance index, TAPSE tricuspid annular plane systolic excursion; sPAP systolic pulmonary arterial pressure, PAS pulmonary arterial stiffness

### Table 4 Bivariate correlation analysis

| Variables               | PAS, kHz/ms |
|-------------------------|-------------|
| C—reactive protein      | r = 0.558, p < 0.001 |
| ESR                     | r = 0.559, p < 0.001 |
| Disease duration         | r = 0.459, p < 0.001 |
| mRSS                    | r = 0.485, p < 0.001 |

PAS pulmonary arterial stiffness. mRSS modified Rodnan skin score, r indicates spearman correlation coefficient

include serum N-terminal probrain natriuretic peptide (NT-proBNP) levels, forced vital capacity (FVC), and diffusion capacity of the lung for carbon monoxide (DLCO) and TTE parameters, can be used periodically. Based on the results of these algorithms, patients are referred for invasive assessment of PAH with RHC [6]. It is clinically hard to diagnose
early changes in pulmonary vasculature because most diagnostic tools focus on sPAP. As long as cardiopulmonary involvement, especially PAH, is the most important cause of death in SSc patients, diagnosing the early stages of the disease is crucial [6].

The early microvasculature changes in SSc patients as a result of the abovementioned pathogenetic processes could be examined by PAS [16, 19]. PAS, the determiner of pulmonary vascular distensibility, and other abnormal flow hemodynamics are strongly associated with impaired elevated right ventricular functions and also with disease severity and poor clinical outcomes in patients with PAH [27]. Singh et al., in their research, investigated pulmonary hemodynamics invasively in patients with PAH and found pulmonary vascular distensibility is an early and sensitive hemodynamic marker of pulmonary vascular disease [26].

The gold-standard assessment of PAS is RHC. Because of its complexity, risks, and widespread inaccessibility, non-invasive methods have been developed [17, 22]. PAS could be determined easily by TTE. The clinical implication of PAS has been validated by several studies. Early detection of impaired pulmonary elasticity and increased PAS was evaluated in polycystic ovary syndrome patients by Abacioglu et al. [1], in cirrhosis patients by Öz et al. [23], in heart failure patients by Yenercag et al. [32], and Yildirim et al. [33], in asthma patients Baysal et al. [3], and in human immunodeficiency virus-infected patients Cerik et al. [10]. But other methods, especially CMR, also can be used. Ray et al. assessed the utility of measuring pulmonary arterial distensibility by CMR as a potential early marker in PAH. In their study, 51 patients with PAH received CMR and RHC on the same day. They compared the results between the healthy subjects and patients with PAH and found that detection of increased PAS by CMR is valuable for early detection of PAH [25]. Although we did not compare our data with other PAH predictors such as peak tricuspid regurgitation velocity, right atrial area, or tissue doppler RV-MPI. Third, there is no data about the patients’ development of overt PAH in clinical follow-up because of the nature of the study.

**Limitations**

The present study has some limitations that need to be addressed:

First of all, the small number of patients and the cross-sectional observational nature of the study are the main limitations. Second, although many clinical studies have proved the validation of clinical efficacy, our data could be confirmed by MRI or RCH. In addition, we did not compare PAS with other PAH predictors such as peak tricuspid regurgitation velocity, right atrial area, or tissue doppler RV-MPI. Third, there is no data about the patients’ development of overt PAH in clinical follow-up because of the nature of the study.

**Conclusion**

The mortal relationship between SSc and PAH is well known. Signs of pulmonary vascular changes might be helpful in the screening process. We know that the earlier we detect the PAH and start treatment, the more positive clinical outcomes will be reached. In this context, as an inexpensive and easily applicable echocardiographic method, PAS might serve as a marker of early detection of PAH in patients with SSc.

**Funding** None.

**Declarations**

**Conflict of interest** No financial or other relationship might be perceived as leading to a conflict of interest.

**Informed Consent** Informed consent was obtained from all participants included in the study.

**References**

1. Abacioglu OO, Gulumsek E, Sumbul H et al (2021) Aumento da rigidez arterial pulmonar e comprometimento do acoplamento ventrículo-direito-artéria pulmonar na SOP. Arq Bras Cardiol 116(4):806–811
2. Avouac J, Airó P, Meune C et al (2010) Prevalence of pulmonary hypertension in systemic sclerosis in European Caucasians and metaanalysis of 5 studies. J Rheumatol 37(11):2290–2298
3. Baysal SS, Has M (2019) Evaluation of pulmonary artery stiffness in newly diagnosed adult patients with asthma. Echocardiography (Mount Kisco, N.Y.), 36(5):870–876
4. Becker MO, Riemekasten G (2016) Risk factors for severity and manifestations in systemic sclerosis and prediction of disease course. Expert Rev Clin Immunol 12(2):115–135
5. Brener MI, Burkhoff D, Sunagawa K (2020) Effective arterial elastance in the pulmonary arterial circulation: derivation, assumptions, and clinical applications. Circ Heart Fail 13(3):e006591
6. Brown ZR, Nikpour M (2020) Screening for pulmonary arterial hypertension in systemic sclerosis: now or never? European J Rheumatology 7(Suppl 3):S187–S192
7. Brown Z, Proudman S, Morrisroe K et al (2021) Screening for the early detection of pulmonary arterial hypertension in patients with systemic sclerosis: a systematic review and meta-analysis of long-term outcomes. Semin Arthritis Rheum 51(3):495–512
8. Bruni C, Cometi L, Gigante A et al (2021) Prediction and primary prevention of major vascular complications in systemic sclerosis. Eur J Intern Med 87:51–58
9. Castelain V, Hervé P, Lecarpentier Y et al (2001) Pulmonary artery flow and stiffness in healthy individuals: non-invasive assessment using cardiac MRI. Clin Radiol 76(2):161. e19-161.e28
10. Cerik IB, Meric M, Gulel O et al (2019) Echocardiographic assessment of pulmonary arterial stiffness in human immunodeficiency virus-infected patients. Echocardiography (Mount Kisco, N.Y.), 36(6):1123–1131
11. Czirják L, Foeldvari I, Müller-Ladner U (2008) Skin involvement in systemic sclerosis. Rheumatology (Oxford) 47(Suppl 5):v44–v45
12. Dogan M, Efe TH, Cimen T et al (2018) Pulmonary arterial hemodynamic assessment by a novel index in systemic sclerosis patients: pulmonary transit time. Lung 196(2):173–178
13. Friesen RM, Schäfer M, Ivy DD et al (2019) Proximal pulmonary vascular stiffness as a prognostic factor in children with pulmonary arterial hypertension. Eur Heart J Cardiovasc Imaging 20(2):209–217
14. Galili N, Humbert M, Vachery J-L et al (2016) 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: the joint task force for the diagnosis and treatment of pulmonary hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Heart J 37(1):67–119
15. Galili N, McLaughlin VV, Rubin LJ et al (2019) An overview of the 6th world symposium on pulmonary hypertension. Eur Respir J 53(1):1802148
16. Görgülü Ş, Eren M, Yildirim A et al (2003) A new echocardiographic approach in assessing pulmonary vascular bed in patients with congenital heart disease: pulmonary artery stiffness. Anadolu kardiyoloji dergisi : AKD = Anatol J of cardiol, 3(2):92–97
17. Horvat D, Zilut A, Orzan RI et al (2021) Aging influences pulmonary artery flow and stiffness in healthy individuals: non-invasive assessment using cardiac MRI. Clin Radiol 76(2):161. e19-161.e28
18. Hsu VM, Moreyra AE, Wilson AC et al (2008) Assessment of pulmonary arterial hypertension in patients with systemic sclerosis: comparison of noninvasive tests with results of right-heart catheterization. J Rheumatol 35(3):458–465
19. Humbert M, Guignabert C, Bonnet S et al (2019) Pathology and pathobiology of pulmonary hypertension: state of the art and research perspectives. Eur Respir J 53:1801887
20. Khanna D, Gladue H, Channick R et al (2013) Recommendations for screening and detection of connective tissue disease-associated pulmonary arterial hypertension. Arthritis Rheum 65(12):3194–3201
21. Moore DF, Stein VD (2021) Overall mortality. J Scleroderma Relat Disorders 6(1):3–10
22. Nemes A, Forster T (2013) A pulmonary artery merysevégének vizsgálata a rutinban alkalmazható klinikai képalkotó módszerekkel. Orv Hetil 154(49):1931–1933
23. Öz A, Činar T, Taş E et al (2021) Assessment of pulmonary arterial stiffness in patients with cirrhosis: a prospective cohort study. Echocardiography (Mount Kisco, N.Y.), 38(1):57–63
24. Porter TR, Shillcutt SK, Adams MS et al (2015) Guidelines for the use of echocardiography as a monitor for therapeutic intervention in adults: a report from the American society of echocardiography. J American Soc of Echocardiography 28(1):40–56
25. Ray JC, Burger C, Mergo P et al (2019) Pulmonary arterial stiffness assessed by cardiovascular magnetic resonance imaging is a predictor of mild pulmonary arterial hypertension. Int J Cardiovasc Imaging 35(10):1881–1892
26. Singh I, Oliveira RKF, Naeije R et al (2019) Pulmonary vascular distensibility and early pulmonary vascular remodeling in pulmonary hypertension. Chest 156(4):724–732
27. Sun W, Chan SY (2018) Pulmonary arterial stiffness: an early and pervasive driver of pulmonary arterial hypertension. Front Med 5:204
28. Theodorakopoulou MP, Minopoulos I, Sarafidis P et al (2021) Vascular endothelial injury assessed with functional techniques in systemic sclerosis patients with pulmonary arterial hypertension versus systemic sclerosis patients without pulmonary arterial hypertension: a systematic review and meta-analysis. Rheumatol Int 41(6):1045–1053
29. Torbicki A (2019) Echocardiographic findings in pulmonary hypertension. In: Camm AJ, Lüscher TF, Maurer G et al (eds) The ESC textbook of cardiovascular medicine. Oxford University Press, Oxford, pp 2502–2506
30. van den Hoogen F, Khanna D, Fransen J et al (2013) Classification criteria for systemic sclerosis: an American college of rheumatology/European league against rheumatism collaborative initiative. Arthritis Rheum 65(11):2737–2747
31. Varga J, Trojanowska M, Kuwana M (2017) Pathogenesis of systemic sclerosis: recent insights of molecular and cellular mechanisms and therapeutic opportunities. J Scleroderma Relat Disorders 2(3):137–152
32. Yenercação M, Arslan U, Dereli S et al (2021) Effects of angiotensin receptor neprilysin inhibition on pulmonary arterial stiffness in heart failure with reduced ejection fraction. Int J Cardiovasc Imaging 37(1):165–173
33. Yildirim E, Celik M, Yuksel UC et al (2017) Relationship between pulmonary arterial hypertension in patients with systemic sclerosis and metaanalysis of 5 studies. J Rheumatol 37(11):2290–2298
34. Yenercação M, Arslan U, Dereli S et al (2021) Effects of angiotensin receptor neprilysin inhibition on pulmonary arterial stiffness in heart failure with reduced ejection fraction. Int J Cardiovasc Imaging 37(1):165–173
35. Yildirim E, Celik M, Yuksel UC et al (2017) Relationship between pulmonary arterial stiffness and functional capacity in patients with heart failure with reduced ejection fraction. Korean Circ J 47(6):929–938

Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.